GSK3923868 / GSK - LARVOL DELTA

A Study to Evaluate the Effect of Itraconazole on the Concentration of GSK3923868 in the Blood in Healthy Participants (clinicaltrials.gov) - P1 | N=20 | Completed | Sponsor: GlaxoSmithKline | Not yet recruiting ➔ Completed

Trial completion • Chronic Obstructive Pulmonary Disease • Respiratory Diseases

Safety, Tolerability and Blood Sampling of GSK3923868 Administered Via Dry Powder Inhaler to Healthy Participants of Chinese, Japanese and European Ancestry (clinicaltrials.gov) - P1 | N=30 | Completed | Sponsor: GlaxoSmithKline | Not yet recruiting ➔ Completed

Trial completion • Infectious Disease • Respiratory Diseases

A Study to Evaluate the Effect of Itraconazole on the Concentration of GSK3923868 in the Blood in Healthy Participants (clinicaltrials.gov) - P1 | N=20 | Not yet recruiting | Sponsor: GlaxoSmithKline

New P1 trial • Chronic Obstructive Pulmonary Disease • Respiratory Diseases

Safety, Tolerability and Blood Sampling of GSK3923868 Administered Via Dry Powder Inhaler to Healthy Participants of Chinese, Japanese and European Ancestry (clinicaltrials.gov) - P1 | N=30 | Not yet recruiting | Sponsor: GlaxoSmithKline

New P1 trial • Infectious Disease • Respiratory Diseases

Efficacy and Safety of GSK3923868 Inhalation Powder, During Experimental Human Rhinovirus Infection in Participants With Mild Asthma (clinicaltrials.gov) - P1 | N=48 | Completed | Sponsor: GlaxoSmithKline | Recruiting ➔ Completed | Phase classification: P1b ➔ P1

Phase classification • Trial completion • Asthma • Chronic Obstructive Pulmonary Disease • Immunology • Infectious Disease • Pulmonary Disease • Respiratory Diseases

Efficacy and Safety of GSK3923868 Inhalation Powder, During Experimental Human Rhinovirus Infection in Participants With Mild Asthma (clinicaltrials.gov) - P1b | N=68 | Recruiting | Sponsor: GlaxoSmithKline | Trial completion date: Jul 2023 ➔ Apr 2024 | Trial primary completion date: Jul 2023 ➔ Apr 2024

Trial completion date • Trial primary completion date • Asthma • Chronic Obstructive Pulmonary Disease • Immunology • Infectious Disease • Pulmonary Disease • Respiratory Diseases

Phase 1, Single and Repeat Dose Study to Assess Safety, Tolerability, and Pharmacokinetics (PK) of GSK3923868 in Participants With Chronic Obstructive Pulmonary Disease (COPD) (clinicaltrials.gov) - P1 | N=12 | Completed | Sponsor: GlaxoSmithKline | Not yet recruiting ➔ Completed

Trial completion • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Phase 1, Single and Repeat Dose Study to Assess Safety, Tolerability, and Pharmacokinetics (PK) of GSK3923868 in Participants With Chronic Obstructive Pulmonary Disease (COPD) (clinicaltrials.gov) - P1 | N=12 | Not yet recruiting | Sponsor: GlaxoSmithKline

New P1 trial • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Efficacy and Safety of GSK3923868 Inhalation Powder, During Experimental Human Rhinovirus Infection in Participants With Mild Asthma (clinicaltrials.gov) - P1b | N=68 | Recruiting | Sponsor: GlaxoSmithKline | Trial completion date: Apr 2023 ➔ Jul 2023 | Trial primary completion date: Apr 2023 ➔ Jul 2023

Trial completion date • Trial primary completion date • Asthma • Chronic Obstructive Pulmonary Disease • Immunology • Infectious Disease • Pulmonary Disease • Respiratory Diseases

Efficacy and Safety of GSK3923868 Inhalation Powder, During Experimental Human Rhinovirus Infection in Participants With Mild Asthma (clinicaltrials.gov) - P1b | N=68 | Recruiting | Sponsor: GlaxoSmithKline | Not yet recruiting ➔ Recruiting

Enrollment open • Asthma • Chronic Obstructive Pulmonary Disease • Immunology • Infectious Disease • Pulmonary Disease • Respiratory Diseases

Safety, Tolerability and Pharmacokinetics of GSK3923868 Inhalation Powder in Healthy Participants and Stable Asthmatics (clinicaltrials.gov) - P1 | N=59 | Completed | Sponsor: GlaxoSmithKline | Recruiting ➔ Completed

Trial completion • Asthma • Chronic Obstructive Pulmonary Disease • Immunology • Respiratory Diseases

Efficacy and Safety of GSK3923868 Inhalation Powder, During Experimental Human Rhinovirus Infection in Participants With Mild Asthma (clinicaltrials.gov) - P1b | N=68 | Not yet recruiting | Sponsor: GlaxoSmithKline

New P1 trial • Asthma • Chronic Obstructive Pulmonary Disease • Immunology • Infectious Disease • Pulmonary Disease • Respiratory Diseases

Safety, Tolerability and Pharmacokinetics of GSK3923868 Inhalation Powder in Healthy Participants and Stable Asthmatics (clinicaltrials.gov) - P1 | N=56 | Recruiting | Sponsor: GlaxoSmithKline | Trial completion date: Feb 2022 ➔ May 2022 | Trial primary completion date: Feb 2022 ➔ May 2022

Trial completion date • Trial primary completion date • Asthma • Chronic Obstructive Pulmonary Disease • Immunology • Respiratory Diseases

Safety, Tolerability and Pharmacokinetics of GSK3923868 Inhalation Powder in Healthy Participants and Stable Asthmatics (clinicaltrials.gov) - P1; N=56; Recruiting; Sponsor: GlaxoSmithKline; Active, not recruiting ➔ Recruiting; Trial completion date: Oct 2021 ➔ Feb 2022; Trial primary completion date: Oct 2021 ➔ Feb 2022

Clinical • Enrollment open • Trial completion date • Trial primary completion date • Asthma • Chronic Obstructive Pulmonary Disease • Immunology • Respiratory Diseases

Safety, Tolerability and Pharmacokinetics of GSK3923868 Inhalation Powder in Healthy Participants and Stable Asthmatics (clinicaltrials.gov) - P1; N=56; Active, not recruiting; Sponsor: GlaxoSmithKline; Recruiting ➔ Active, not recruiting

Clinical • Enrollment closed • Asthma • Chronic Obstructive Pulmonary Disease • Immunology • Respiratory Diseases

Safety, Tolerability and Pharmacokinetics of GSK3923868 Inhalation Powder in Healthy Participants and Stable Asthmatics (clinicaltrials.gov) - P1; N=56; Recruiting; Sponsor: GlaxoSmithKline; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Asthma • Chronic Obstructive Pulmonary Disease • Immunology • Respiratory Diseases

Safety, Tolerability and Pharmacokinetics of GSK3923868 Inhalation Powder in Healthy Participants and Stable Asthmatics (clinicaltrials.gov) - P1; N=56; Not yet recruiting; Sponsor: GlaxoSmithKline

Clinical • New P1 trial • Asthma • Chronic Obstructive Pulmonary Disease • Respiratory Diseases